Please use this identifier to cite or link to this item: http://repository.tma.uz/xmlui/handle/1/3055
Full metadata record
DC FieldValueLanguage
dc.contributor.authorДадабаева Н.А., Махмудова М.С., Ахмедова Д.Т-
dc.date.accessioned2022-10-11T09:00:15Z-
dc.date.available2022-10-11T09:00:15Z-
dc.date.issued2022-
dc.identifier.issn2181-7812-
dc.identifier.urihttp://repository.tma.uz/xmlui/handle/1/3055-
dc.description.abstractTo date, the treatment of OA is primarily aimed at the symptoms of the disease, i.e., to reduce pain and improve the functional state of the joints. The use of NSAIDs allows you to quickly reduce the intensity of pain and accelerate the recovery of motor activity in OA. However, the use of this group of drugs is associated with the development of adverse events from the gastrointestinal tract, cardiovascular system, kidneys and other organs, which is especially important in comorbid conditions in elderly patients. In this regard, it becomes clear that there is a high interest in a group of drugs with delayed symptomatic action, which have proven themselves excellently in arthrological practiceen_US
dc.language.isootheren_US
dc.publisherУзбекистанen_US
dc.subjectosteoarthritis, chondroitin sulfate, glucosamine, ARTRA® MSMen_US
dc.titleНовые фармакологические подходы к лечению остеоартроза крупных суставовen_US
dc.typeArticleen_US
Appears in Collections:Thesis, Articles

Files in This Item:
File Description SizeFormat 
5.pdfНовые фармакологические подходы к лечению остеоартроза крупных суставов718.49 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.